home.aspx
 
EVENTS

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...

Medicinal and Pharmaceutical Chemistry
MEDICINAL AND PHARMACEUTICAL CHEMISTRY
December 16-17, 2019
Medicinal Chemistry is the science of design and chemical synthesis focusing mainly on small organic molecules and their development of pharmaceutical agents, or bio-active molecules (drugs). Pharmaceutical Chemistry is the same plus the science of pharmaceutical and biomedical analysis to the synth...

Boehringer Ingelheim

For more than 130 years, Boehringer Ingelheim has been committed to the research, development, and manufacturing of new medications with high therapeutic value for people and animals. As a family-owned pharmaceutical company, Boehringer Ingelheim is able to take a long-term view and invest heavily in research and development.

RELATED NEWS


The US Food and Drug Administration (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) has voted against Boehringer Ingelheim and Eli Lilly’s diabetes drug, empagliflozin. The panel voted 14 to 2, saying that the benefits of 2.5mg dose of the drug do not outweigh its risks as an adjunct to insulin in adults with type 1 diabetes. Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2). In higher doses, the inhibitors were associated with a life-threatening ...

READ MORE

The Institute for Clinical and Economic Review (ICER) started giving Novo Nordisk a hard time about the cost-effectiveness of its oral version of semaglutide, Rybelsus, before the drug was even approved in September. Now the product has its price tag— $772 per month, on par with comparable injectables—yet ICER still isn’t happy. ICER released a report Friday concluding that if Rybelsus is prescribed as an add-on treatment to metformin in Type 2 diabetes, it will be less cost-ef...

READ MORE

LA-based biotech ImaginAb has signed a multi-party agreement with pharma giants AstraZeneca, Pfizer, and Takeda, for technology that allows scientists to see inside tumours, and monitor whether immunotherapies are taking effect. ImaginAb’s imaging technology targets and visualises CD8+ T cells that are called in to attack tumours by immunotherapies. The company’s ‘Minibody’ platform can assess the immunological status of each cancer lesion within a patient, potentially en...

READ MORE

Mylan’s hopes of grabbing a slice of the big US market for insulin glargine – the active ingredient in Sanofi’s Lantus blockbuster – have been dealt a blow. The FDA has issued a second complete response letter (CRL) rejecting the marketing application for the biosimilar after uncovering quality problems at Biocon – Mylan’s partner for the drug – in a pre-approval inspection of one of its manufacturing facilities in Malaysia. Biocon played down the implic...

READ MORE

Boehringer Ingelheim has announced its acquisition of all shares of AMAL Therapeutics, a private Swiss biotechnology company focused on cancer immunotherapy. AMAL’s lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month, and Boehringer Ingelheim plans to develop new therapies by combining assets from its cancer immunology portfolio with AMAL’s proprietary KISIMA immunisation platform. “Acquiring AM...

READ MORE

Bayer has delayed a planned sale of its animal health unit to private equity interests in order to explore a merger with US firm Elanco, claims Reuters. Citing three separate anonymous sources, the news agency says the two companies are already working with banks to ensure any merger would secure regulatory approvals. However it also suggests Elanco may not have the cash needed to complete the deal. Elanco – formerly part of Eli Lilly before being spun off last year – is the fourth-l...

READ MORE

Englands cost watchdogs wont get behind AstraZeneca blockbuster Tagrisso in previously untreated patients with EGFR-mutated lung cancer. But in a change of events, they’re instead backing a Pfizer challenger. Friday, the National Institute for Health and Care Excellence (NICE) deemed Tagrisso too expensive for routine NHS use, dealing a blow to AZ’s sales ambitions. NICE already endorses Boehringer Ingelheim’s Gilotrif, Roche’s Tarceva and AstraZeneca’s own Iressa, ...

READ MORE

Boehringer Ingelheim and Eli Lilly have announced full data from the CAROLINAtrial, in which Trajenta (linagliptin) demonstrated no increased cardiovascular risk compared to glimepiride  in adults with type II diabetes and cardiovascular risk. The study is the only active-comparator cardiovascular outcome trial for a dipeptidyl peptidase-4 (DPP-4) inhibitor, and also assessed linagliptin safety over the longest period ever studied in a DPP-4 inhibitor cardiovascular outcome trial, with a me...

READ MORE

On Sept. 1, Brandicourt will retire, and Hudson—who was formerly president of Novartis’ pharma business—will take the reins at the French drugmaker. The change in leadership comes after Sanofi in March confirmed it was working on succession planning for Brandicourt, who took the helm at Sanofi in April 2015. At the time, the CEO was two years away from his 65th birthday, and the company sets that age limit for its leaders. It also comes after several years of turmoil at the Fre...

READ MORE

А leading pharmaceutical firm Boehringer Ingelheim has teamed up with blockchain-based healthcare platform Solve.Care, according to a press release shared with Cointelegraph on June 6. Germany-based Boehringer, one of the world’s 20 largest pharma companies, and Solve.Care are planning to build a blockchain and digital asset-powered network for trusted sharing of data about patients with diabetes. Based on Solve.Care’s blockchain platform, the new healthcare system is known as the Di...

READ MORE

EVENTS

International Conference on Metabolic Diseases and Liver Cancer
INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER
December 16-17, 2019
“INTERNATIONAL CONFERENCE ON METABOLIC DISEASES AND LIVER CANCER ’’ is organized in order to bring light and anticipate to the dark sides of human liver cancer and irregular human metabolic diseases which are prevailing worldwide. This conference is effective on all sides as it giv...

Medicinal and Pharmaceutical Chemistry
MEDICINAL AND PHARMACEUTICAL CHEMISTRY
December 16-17, 2019
Medicinal Chemistry is the science of design and chemical synthesis focusing mainly on small organic molecules and their development of pharmaceutical agents, or bio-active molecules (drugs). Pharmaceutical Chemistry is the same plus the science of pharmaceutical and biomedical analysis to the synth...